Treatment of metastatic rhabdoid tumor of the kidney

Lars Wagner; D. Ashley Hill; Christine Fuller; Márcia Pedrosa; Manoo Bhakta; Arie Perry; Jeffrey S. Dome

doi:10.1097/00043426-200206000-00012

Treatment of metastatic rhabdoid tumor of the kidney

Lars Wagner, D. Ashley Hill, Christine Fuller, Márcia Pedrosa, Manoo Bhakta, Arie Perry, Jeffrey S. Dome

Division of Anatomic and Molecular Pathology (AMP)

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Metastatic rhabdoid tumor of the kidney (RTK) is a highly lethal malignancy; only one survivor with stage 4 disease has been reported. The authors reviewed the cases of two patients with metastatic RTK who had excellent responses to therapy. Both patients were treated with radiation therapy and alternating courses of ifosfamide, carboplatin, and etoposide (ICE) and vincristine, doxorubicin, and cyclophosphamide (VDC). The patients are without evidence of disease at 24 months and 12 months from the detection of metastasis. Alternating courses of ICE and VDC have activity against metastatic RTK. This combination of agents warrants prospective investigation in clinical trials.

Original language	English
Pages (from-to)	385-388
Number of pages	4
Journal	Journal of Pediatric Hematology/Oncology
Volume	24
Issue number	5
DOIs	https://doi.org/10.1097/00043426-200206000-00012
State	Published - 2002

Keywords

Atypical teratoid/rhabdoid tumor
INI-1
Rhabdoid tumor
Snf5
Wilms tumor

Access to Document

10.1097/00043426-200206000-00012

Cite this

@article{90c3d8b9e0234f1899076d8719fade0f,

title = "Treatment of metastatic rhabdoid tumor of the kidney",

abstract = "Metastatic rhabdoid tumor of the kidney (RTK) is a highly lethal malignancy; only one survivor with stage 4 disease has been reported. The authors reviewed the cases of two patients with metastatic RTK who had excellent responses to therapy. Both patients were treated with radiation therapy and alternating courses of ifosfamide, carboplatin, and etoposide (ICE) and vincristine, doxorubicin, and cyclophosphamide (VDC). The patients are without evidence of disease at 24 months and 12 months from the detection of metastasis. Alternating courses of ICE and VDC have activity against metastatic RTK. This combination of agents warrants prospective investigation in clinical trials.",

keywords = "Atypical teratoid/rhabdoid tumor, INI-1, Rhabdoid tumor, Snf5, Wilms tumor",

author = "Lars Wagner and {Ashley Hill}, D. and Christine Fuller and M{\'a}rcia Pedrosa and Manoo Bhakta and Arie Perry and Dome, {Jeffrey S.}",

year = "2002",

doi = "10.1097/00043426-200206000-00012",

language = "English",

volume = "24",

pages = "385--388",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

number = "5",

}

TY - JOUR

T1 - Treatment of metastatic rhabdoid tumor of the kidney

AU - Wagner, Lars

AU - Ashley Hill, D.

AU - Fuller, Christine

AU - Pedrosa, Márcia

AU - Bhakta, Manoo

AU - Perry, Arie

AU - Dome, Jeffrey S.

PY - 2002

Y1 - 2002

N2 - Metastatic rhabdoid tumor of the kidney (RTK) is a highly lethal malignancy; only one survivor with stage 4 disease has been reported. The authors reviewed the cases of two patients with metastatic RTK who had excellent responses to therapy. Both patients were treated with radiation therapy and alternating courses of ifosfamide, carboplatin, and etoposide (ICE) and vincristine, doxorubicin, and cyclophosphamide (VDC). The patients are without evidence of disease at 24 months and 12 months from the detection of metastasis. Alternating courses of ICE and VDC have activity against metastatic RTK. This combination of agents warrants prospective investigation in clinical trials.

AB - Metastatic rhabdoid tumor of the kidney (RTK) is a highly lethal malignancy; only one survivor with stage 4 disease has been reported. The authors reviewed the cases of two patients with metastatic RTK who had excellent responses to therapy. Both patients were treated with radiation therapy and alternating courses of ifosfamide, carboplatin, and etoposide (ICE) and vincristine, doxorubicin, and cyclophosphamide (VDC). The patients are without evidence of disease at 24 months and 12 months from the detection of metastasis. Alternating courses of ICE and VDC have activity against metastatic RTK. This combination of agents warrants prospective investigation in clinical trials.

KW - Atypical teratoid/rhabdoid tumor

KW - INI-1

KW - Rhabdoid tumor

KW - Snf5

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=0036064231&partnerID=8YFLogxK

U2 - 10.1097/00043426-200206000-00012

DO - 10.1097/00043426-200206000-00012

M3 - Article

C2 - 12142788

AN - SCOPUS:0036064231

SN - 1077-4114

VL - 24

SP - 385

EP - 388

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 5

ER -

Treatment of metastatic rhabdoid tumor of the kidney

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this